Evidence map›Paper›PMID 17590176›Full record

Trial reportClinical and experimental immunology2007

Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients.

M Lorea Baroja, P V Kirjavainen, S Hekmat, G Reid

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05942586 (Systematic Functional Characterization of the Effect of Synbiotic Supplementation with Limosilactobacillus Reuteri PB-W1™ and Prebiotics on Markers of Immune Health, Host Metabolome and Gut Microbiome in Adults with BMI 30-40 Kg/m²), which is not on this map. Cited by 79 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 3 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05942586 nacompletednot on this mapstarted 2023, after this paper: background citation

Systematic Functional Characterization of the Effect of Synbiotic Supplementation with Limosilactobacillus Reuteri PB-W1™ and Prebiotics on Markers of Immune Health, Host Metabolome and Gut Microbiome in Adults with BMI 30-40 Kg/m²

TypeinterventionalSponsorUniversity College CorkRan2023 to 2024Enrolled137ConditionsObesityArmsProbiotic capsule (L. reuteri PB-W1™), Placebo sachet, Prebiotic sachet (Prebiotic Blend), Placebo capsule, Probiotic capsule (L. reuteri PB-W1™), Prebiotic sachet (Prebiotic Blend), Placebo sachet, Placebo capsule
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 234 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Trial
  6. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Gut microbes · 2025
    Review
  14. Review
  15. Article
  16. A Meta-analysis of the Effect of ProbioticMedeniyet medical journal · 2024
    Article
  17. Is the Mediterranean Diet in Inflammatory Bowel Diseases Ready for Prime Time?Journal of the Canadian Association of Gastroenterology · 2024
    Review
  18. Effects of fermentedFrontiers in cellular and infection microbiology · 2024
    Article
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

M Lorea BarojaCanadian Research and Development Centre for Probiotics, The Lawson Health Research Institute, London, Ontario, Canada.
P V Kirjavainen
S Hekmat
G Reid
Lawson Health Research Institute · CAUniversity of Eastern Finland · FIWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our aim was to assess anti-inflammatory effects on the peripheral blood of subjects with inflammatory bowel disease (IBD) who consumed probiotic yogurt for 1 month. We studied 20 healthy controls and 20 subjects with IBD, 15 of whom had Crohn's disease and five with ulcerative colitis. All the subjects consumed Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 supplemented yogurt for 30 days. The presence of putative regulatory T (T(reg)) cells (CD4(+) CD25(high)) and cytokines in T cells, monocytes and dendritic cells (DC) was determined by flow cytometry from peripheral blood before and after treatment, with or without ex vivo stimulation. Serum and faecal cytokine concentrations were determined by enzyme-linked immunosorbent assays. The proportion of CD4(+) CD25(high) T cells increased significantly (P = 0.007) in IBD patients, mean (95% confidence interval: CI) 0.84% (95% CI 0.55-1.12) before and 1.25% (95% CI 0.97-1.54) after treatment, but non-significantly in controls. The basal proportion of tumour necrosis factor (TNF)-alpha(+)/interleukin (IL)-12(+) monocytes and myeloid DC decreased in both subject groups, but of stimulated cells only in IBD patients. Also serum IL-12 concentrations and proportions of IL-2(+) and CD69(+) T cells from stimulated cells decreased in IBD patients. The increase in CD4(+) CD25(high) T cells correlated with the decrease in the percentage of TNF-alpha- or IL-12-producing monocytes and DC. The effect of the probiotic yogurt was confirmed by a follow-up study in which subjects consumed the yogurt without the probiotic organisms. Probiotic yogurt intake was associated with significant anti-inflammatory effects that paralleled the expansion of peripheral pool of putative T(reg) cells in IBD patients and with few effects in controls.

Indexed as

YogurtAdultCD4-Positive T-LymphocytesCell ProliferationCells, CulturedCytokinesDendritic CellsFecesHumansInflammatory Bowel DiseasesMiddle AgedMonocytesProbioticsSingle-Blind MethodT-Lymphocyte SubsetsTreatment OutcomeCytokines

Identifiers

PMID17590176
PMCPMC2219330
OpenAlexW1546580461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.